Skip to main content
Premium Trial:

Request an Annual Quote

Evogene Lands $2M Investment from AquAgro

NEW YORK (GenomeWeb News) – Evogene said today that the venture capital group AquAgro Fund has invested $2 million in the company through a private placement.
 
Evogene, a Rehovot, Israel-based company, uses computational gene discovery technologies, high-throughput selection systems, and advanced breeding methods to develop plants for the ag-biotech and biofuel industries.
 
AquAgro will acquire 1,107,700 newly issued ordinary shares at a price of 6.5 NIS ($1.86) per share and will receive 651,584 warrants to purchase the same number of shares at 11.05 NIS. The fund will hold a 5 percent stake in Evogene following the investment.
 
Evogene also retains the right to issue additional ordinary shares to AquAgro until May 31, 2011, at a price of 4.5 NIS per share, up to an additional $2 million in investment, Evogene said.
 
AquAgro and Evogene “share a commitment to address major problems already facing the critically important worldwide alternative energy and food and feed fields,” said Evogene President and CEO Ofer Haviv in a statement.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.